Evotec and Bristol Myers Squibb are deepening their partnership on molecular glue degraders. Molecular glues are the next generation of targeted protein degraders, small molecules that lead a disease-causing protein to bind to an E3 ubiquitin ligase. This binding causes the protein to be degraded by cellular machinery. The companies will extend their partnership, started in 2018, by 8 years. Evotec will receive $200 million and milestone payments that could amount to $5 billion.